IHH Healthcare
Level 35, Mercu Aspire, 3 Jalan Bangsar, KL Eco City, Kuala Lumpur, Wilayah Persekutuan, 59200, Malaysia
Overview
IHH Healthcare Berhad ("IHH or the Group") is a leading international provider of premium healthcare services in markets where the demand for quality healthcare is growing rapidly – specifically in Asia and Central & Eastern Europe, the Middle East and North Africa ("CEEMENA"). We are the world's second-largest listed healthcare operator by market capitalisation and are today the leading player in our home markets of Singapore, Malaysia and Turkey, and the key markets of the People's Republic of China ("China"), Hong Kong and India. We are also present in Brunei, Vietnam, United Arab Emirates ("the UAE"), Macedonia and Iraq.
- Total investments
- 2
- Lead investments
- 1
- Investments · 12mo
- 0
- Active investors
- 4
Sector focus
- Health Care
- Hospital
Investment portfolio
- Doctor Anywhere
Participated · Series C · Aug 2021
Doctor Anywhere operates a digital platform that enables patients to access medical assistance on demand, complemented by offline resources such as GP clinics and mobile healthcare services. Its services cover management of a wide range of acute and chronic conditions for adults and children, including home-based health screenings, vaccinations, medication access and distribution, COVID-19 testing, mental wellness support, and nutrition and fitness counselling. The company was launched in 2017 and is led by founder and CEO Lim Wai Mun. Since launch it has grown to serve more than 1.5 million users and is available in Singapore, Malaysia, Thailand, Vietnam, and the Philippines. The group recently established regional tech hubs in Bangalore, India, and Ho Chi Minh City, Vietnam. Doctor Anywhere intends to use new funds to bolster its market leadership, deepen presence in existing markets, and expand into new markets.
- Lucence Diagnostics
Led · Series A · Nov 2019
Lucence develops non-invasive blood-based genomic tests (LiquidHALLMARK) that detect cancer-related genetic mutations and cancer-causing viruses with a single assay and screens for signs of 14 cancer types. Its proprietary amplicon-sequencing targets specific genomic regions for mutations and the company positions the test for screening, diagnosis, treatment selection and monitoring. LiquidHALLMARK has been used by oncologists for about 1,000 patients in Asia so far. Lucence’s Singapore lab holds CLIA certification and CAP accreditation, enabling use by U.S. doctors, and the company is building a Bay Area lab to reduce turnaround times. The company plans to expand further in North America and East Asia and to make its products commercially available to more patients in Asia and North America. It is also preparing two prospective clinical trials, including a sensitivity study in late-stage patients and an early-stage detection study across multiple cancers, and is designing a 100,000-participant validation study with first patient recruitment planned for the middle of next year.